How we treat a hemophilia A patient with a factor VIII inhibitor
Author:
Affiliation:
1. AFLAC Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA; and
2. Blood Research Institute, The Blood Center of Wisconsin, Milwaukee
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/113/1/11/1302469/zh800109000011.pdf
Reference73 articles.
1. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.;Darby;J Thromb Haemost,2004
2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.;Ehrenforth;Lancet,1992
3. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.;Kempton;J Thromb Haemost,2006
4. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.;Soucie;Blood,2004
5. Proceedings: a more uniform measurement of factor VIII inhibitors.;Kasper;Thromb Diath Haemorrh,1975
Cited by 140 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Activated Factor X delivered by Adeno-Associated virus significantly inhibited bleeding and alleviated hemophilia A/B arthropathy in hemophilia mice;2024-01-05
2. Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective;Saudi Pharmaceutical Journal;2023-12
3. Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline;Blood Reviews;2023-11
4. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study;Expert Review of Hematology;2023-09-07
5. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3